Our top pick for
Building a portfolio
Arcutis Biotherapeutics, Inc is a biotechnology business based in the US. Arcutis Biotherapeutics shares (ARQT) are listed on the NASDAQ and all prices are listed in US Dollars. Arcutis Biotherapeutics employs 54 staff and has a market cap (total outstanding shares value) of USD$1.4 billion.
|52-week range||USD$17.51 - USD$39.8527|
|50-day moving average||USD$30.42|
|200-day moving average||USD$27.8103|
|Wall St. target price||USD$56.83|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-1.1466|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Gross profit TTM||USD$0|
|Return on assets TTM||-42.95%|
|Return on equity TTM||-72.93%|
|Market capitalisation||USD$1.4 billion|
TTM: trailing 12 months
There are currently 1.9 million Arcutis Biotherapeutics shares held short by investors – that's known as Arcutis Biotherapeutics's "short interest". This figure is 19% up from 1.6 million last month.
There are a few different ways that this level of interest in shorting Arcutis Biotherapeutics shares can be evaluated.
Arcutis Biotherapeutics's "short interest ratio" (SIR) is the quantity of Arcutis Biotherapeutics shares currently shorted divided by the average quantity of Arcutis Biotherapeutics shares traded daily (recently around 196520.40169133). Arcutis Biotherapeutics's SIR currently stands at 9.46. In other words for every 100,000 Arcutis Biotherapeutics shares traded daily on the market, roughly 9460 shares are currently held short.
However Arcutis Biotherapeutics's short interest can also be evaluated against the total number of Arcutis Biotherapeutics shares, or, against the total number of tradable Arcutis Biotherapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Arcutis Biotherapeutics's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Arcutis Biotherapeutics shares in existence, roughly 40 shares are currently held short) or 0.0622% of the tradable shares (for every 100,000 tradable Arcutis Biotherapeutics shares, roughly 62 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Arcutis Biotherapeutics.
Find out more about how you can short Arcutis Biotherapeutics stock.
We're not expecting Arcutis Biotherapeutics to pay a dividend over the next 12 months.
Arcutis Biotherapeutics, Inc. , a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019.
Steps to owning and managing ZTO, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZOM, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZI, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZKIN, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZION, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZIONL, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZNTL, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZGYH, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZEAL, with 24-hour and historical pricing before you buy.
Steps to owning and managing CTIB, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.